

(51) International Patent Classification:

A61B 5/145 (2006.01) A61L 2/28 (2006.01)
A61B 5/00 (2006.01) A61B 90/00 (2016.01)

(21) International Application Number:

PCT/EP2021/054365

(22) International Filing Date:

23 February 2021 (23.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20159511.3 26 February 2020 (26.02.2020) EP

(71) Applicant (for all designated States except DE, US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for DE only): **ROCHE DIABETES CARE GMBH** [DE/DE]; Patent Department, Sandhofer Strasse 116, 68305 Mannheim (DE).

(71) Applicant (for US only): **ROCHE DIABETES CARE, INC.** [US/US]; 9115 Hague Road, Indianapolis, Indiana 46250 (US).

(72) Inventors: **LIST, Hans**; c/o Roche Diabetes Care GmbH, Sandhofer Strasse 116, 68305 Mannheim (DE). **RIEBEL, Stefan**; c/o Roche Diabetes Care GmbH, Sandhofer Strasse 116, 68305 Mannheim (DE). **RITTINGHAUS, Andrea**; c/o Roche Diabetes Care GmbH, Sandhofer Strasse 116, 68305 Mannheim (DE).

(74) Agent: **GEIS, Vanessa**; Patent Department, Sandhofer Strasse 116, 68305 Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: MEDICAL SYSTEM AND METHOD OF STERILITY TESTING THE MEDICAL SYSTEM




Fig. 2

(57) Abstract: The invention discloses a medical system (144). The medical system (144) comprises: i) a housing (146); ii) a preassembled functional module (110) received in the housing (146), the preassembled functional module (110) comprising a. an analyte sensor (112) for detecting at least one analyte in a body fluid of a user; b. an electronics unit (120) electrically connected to the analyte sensor (112); and c. an insertion component (114) for inserting the analyte sensor (112) into a body tissue of the user; and iii) at least one removable protective cap (148) connected to the housing (146), covering the preassembled functional module (110), wherein the preassembled functional module (110) further comprises at least one sterility cap (116), which at least partially surrounds the insertion component (114), wherein the at least one sterility cap (116) is at least partially surrounded by the protective cap (148), wherein the sterility cap (116) comprises at least one sterility testing access (140), the sterility testing access (140) comprising at least one of a septum (142) and a multiple-step sealing (162). Further, methods of providing the medical system (144) and of sterility testing of the medical system (144) are disclosed.

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*